<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7462603\results\search\disease\results.xml">
  <result pre="Inc. pmcid: 7462603S0196-9781(20)30151-0 doi: 10.1016/j.peptides.2020.170402170402 : Review Peptides to combat" exact="viral" post="infectious diseases Al-AzzamShamsaDingYunb1LiuJinshab1PandyaPriyankab1TingJoey Paolob1AfsharSepidehb*[a], [b], â�ŽCorresponding author. 1These authors"/>
  <result pre="pmcid: 7462603S0196-9781(20)30151-0 doi: 10.1016/j.peptides.2020.170402170402 : Review Peptides to combat viral" exact="infectious diseases" post="Al-AzzamShamsaDingYunb1LiuJinshab1PandyaPriyankab1TingJoey Paolob1AfsharSepidehb*[a], [b], â�ŽCorresponding author. 1These authors contributed equally"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="long as the COVID-19 resource centre remains active. Highlights â€¢Five" exact="viral" post="infectious diseases with high global prevalence are discussed. â€¢Those"/>
  <result pre="as the COVID-19 resource centre remains active. Highlights â€¢Five viral" exact="infectious diseases" post="with high global prevalence are discussed. â€¢Those diseases include"/>
  <result pre="medicines. â€¢Potential of peptides in therapy, vaccine, and diagnostic of" exact="viral infection" post="diseases are addressed. â€¢Peptide-based candidates in pre-clinical and clinical"/>
  <result pre="â€¢Potential of peptides in therapy, vaccine, and diagnostic of viral" exact="infection" post="diseases are addressed. â€¢Peptide-based candidates in pre-clinical and clinical"/>
  <result pre="â€¢Peptide-based candidates in pre-clinical and clinical stages are highlighted. Abstract" exact="Viral" post="infectious diseases have resulted in millions of deaths throughout"/>
  <result pre="candidates in pre-clinical and clinical stages are highlighted. Abstract Viral" exact="infectious diseases" post="have resulted in millions of deaths throughout history and"/>
  <result pre="health officials and government organizations to detect, treat, and prevent" exact="viral infection." post="However, the complicated life cycle and rapid genetic mutations"/>
  <result pre="as a tool to combat the spread and re-emergence of" exact="viral infection." post="This article provides an overview of five viral infectious"/>
  <result pre="of viral infection. This article provides an overview of five" exact="viral" post="infectious diseases with high global prevalence: influenza, chronic hepatitis"/>
  <result pre="viral infection. This article provides an overview of five viral" exact="infectious diseases" post="with high global prevalence: influenza, chronic hepatitis B, acquired"/>
  <result pre="of five viral infectious diseases with high global prevalence: influenza," exact="chronic hepatitis" post="B, acquired immunodeficiency syndrome, severe acute respiratory syndrome, and"/>
  <result pre="five viral infectious diseases with high global prevalence: influenza, chronic" exact="hepatitis" post="B, acquired immunodeficiency syndrome, severe acute respiratory syndrome, and"/>
  <result pre="infectious diseases with high global prevalence: influenza, chronic hepatitis B," exact="acquired immunodeficiency syndrome," post="severe acute respiratory syndrome, and coronavirus disease 2019. The"/>
  <result pre="diseases with high global prevalence: influenza, chronic hepatitis B, acquired" exact="immunodeficiency" post="syndrome, severe acute respiratory syndrome, and coronavirus disease 2019."/>
  <result pre="global prevalence: influenza, chronic hepatitis B, acquired immunodeficiency syndrome, severe" exact="acute" post="respiratory syndrome, and coronavirus disease 2019. The current and"/>
  <result pre="prevalence: influenza, chronic hepatitis B, acquired immunodeficiency syndrome, severe acute" exact="respiratory" post="syndrome, and coronavirus disease 2019. The current and potential"/>
  <result pre="B, acquired immunodeficiency syndrome, severe acute respiratory syndrome, and coronavirus" exact="disease" post="2019. The current and potential peptide-based therapies, vaccines, and"/>
  <result pre="current and potential peptide-based therapies, vaccines, and diagnostics for each" exact="disease" post="are discussed. Abbreviations Flu, influenza HBV, hepatitis B virus"/>
  <result pre="diagnostics for each disease are discussed. Abbreviations Flu, influenza HBV," exact="hepatitis" post="B virus CHB, chronic hepatitis B AIDS, acquired immunodeficiency"/>
  <result pre="are discussed. Abbreviations Flu, influenza HBV, hepatitis B virus CHB," exact="chronic hepatitis" post="B AIDS, acquired immunodeficiency syndrome HIV, human immunodeficiency virus"/>
  <result pre="discussed. Abbreviations Flu, influenza HBV, hepatitis B virus CHB, chronic" exact="hepatitis" post="B AIDS, acquired immunodeficiency syndrome HIV, human immunodeficiency virus"/>
  <result pre="influenza HBV, hepatitis B virus CHB, chronic hepatitis B AIDS," exact="acquired immunodeficiency syndrome" post="HIV, human immunodeficiency virus SARS, severe acute respiratory syndrome"/>
  <result pre="HBV, hepatitis B virus CHB, chronic hepatitis B AIDS, acquired" exact="immunodeficiency" post="syndrome HIV, human immunodeficiency virus SARS, severe acute respiratory"/>
  <result pre="hepatitis B virus CHB, chronic hepatitis B AIDS, acquired immunodeficiency" exact="syndrome" post="HIV, human immunodeficiency virus SARS, severe acute respiratory syndrome"/>
  <result pre="CHB, chronic hepatitis B AIDS, acquired immunodeficiency syndrome HIV, human" exact="immunodeficiency" post="virus SARS, severe acute respiratory syndrome SARS-CoV-1, severe acute"/>
  <result pre="AIDS, acquired immunodeficiency syndrome HIV, human immunodeficiency virus SARS, severe" exact="acute" post="respiratory syndrome SARS-CoV-1, severe acute respiratory syndrome coronavirus 1"/>
  <result pre="acquired immunodeficiency syndrome HIV, human immunodeficiency virus SARS, severe acute" exact="respiratory" post="syndrome SARS-CoV-1, severe acute respiratory syndrome coronavirus 1 COVID-19,"/>
  <result pre="immunodeficiency syndrome HIV, human immunodeficiency virus SARS, severe acute respiratory" exact="syndrome" post="SARS-CoV-1, severe acute respiratory syndrome coronavirus 1 COVID-19, coronavirus"/>
  <result pre="human immunodeficiency virus SARS, severe acute respiratory syndrome SARS-CoV-1, severe" exact="acute" post="respiratory syndrome coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2,"/>
  <result pre="immunodeficiency virus SARS, severe acute respiratory syndrome SARS-CoV-1, severe acute" exact="respiratory" post="syndrome coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2, severe"/>
  <result pre="virus SARS, severe acute respiratory syndrome SARS-CoV-1, severe acute respiratory" exact="syndrome" post="coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2, severe acute"/>
  <result pre="syndrome SARS-CoV-1, severe acute respiratory syndrome coronavirus 1 COVID-19, coronavirus" exact="disease" post="2019 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 AMP,"/>
  <result pre="respiratory syndrome coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 AMP, antimicrobial peptides bnAbs, broadly"/>
  <result pre="syndrome coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 AMP, antimicrobial peptides bnAbs, broadly naturalizing"/>
  <result pre="coronavirus 1 COVID-19, coronavirus disease 2019 SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 AMP, antimicrobial peptides bnAbs, broadly naturalizing antibodies"/>
  <result pre="matrix-2 FDA, U.S. Food and Drug Administration MDCK, Madin-Darby Canine" exact="Kidney" post="cells PLpro, Papain-like protease 3CLpro, 3C-like protease Mpro, main"/>
  <result pre="E, Envelope protein M, Membrane glycoprotein N, Nucleocapsid protein HCV," exact="hepatitis C" post="virus RSV, Respiratory syncytial viral, ACE2, Angiotensin-converting enzyme CPE,"/>
  <result pre="Membrane glycoprotein N, Nucleocapsid protein HCV, hepatitis C virus RSV," exact="Respiratory" post="syncytial viral, ACE2, Angiotensin-converting enzyme CPE, Cytopathic effect MOE,"/>
  <result pre="polymerase chain reaction qRT-PCR, quantitative real-time PCR Keywords Peptides Influenza" exact="Chronic" post="hepatitis B Acquired immunodeficiency syndrome Severe acute respiratory syndrome"/>
  <result pre="chain reaction qRT-PCR, quantitative real-time PCR Keywords Peptides Influenza Chronic" exact="hepatitis" post="B Acquired immunodeficiency syndrome Severe acute respiratory syndrome Coronavirus"/>
  <result pre="qRT-PCR, quantitative real-time PCR Keywords Peptides Influenza Chronic hepatitis B" exact="Acquired" post="immunodeficiency syndrome Severe acute respiratory syndrome Coronavirus disease 2019"/>
  <result pre="quantitative real-time PCR Keywords Peptides Influenza Chronic hepatitis B Acquired" exact="immunodeficiency" post="syndrome Severe acute respiratory syndrome Coronavirus disease 2019 1"/>
  <result pre="real-time PCR Keywords Peptides Influenza Chronic hepatitis B Acquired immunodeficiency" exact="syndrome" post="Severe acute respiratory syndrome Coronavirus disease 2019 1 Introduction"/>
  <result pre="PCR Keywords Peptides Influenza Chronic hepatitis B Acquired immunodeficiency syndrome" exact="Severe" post="acute respiratory syndrome Coronavirus disease 2019 1 Introduction Viral"/>
  <result pre="Keywords Peptides Influenza Chronic hepatitis B Acquired immunodeficiency syndrome Severe" exact="acute" post="respiratory syndrome Coronavirus disease 2019 1 Introduction Viral infectious"/>
  <result pre="Peptides Influenza Chronic hepatitis B Acquired immunodeficiency syndrome Severe acute" exact="respiratory" post="syndrome Coronavirus disease 2019 1 Introduction Viral infectious diseases"/>
  <result pre="Influenza Chronic hepatitis B Acquired immunodeficiency syndrome Severe acute respiratory" exact="syndrome" post="Coronavirus disease 2019 1 Introduction Viral infectious diseases have"/>
  <result pre="hepatitis B Acquired immunodeficiency syndrome Severe acute respiratory syndrome Coronavirus" exact="disease" post="2019 1 Introduction Viral infectious diseases have had a"/>
  <result pre="syndrome Severe acute respiratory syndrome Coronavirus disease 2019 1 Introduction" exact="Viral" post="infectious diseases have had a catastrophic impact in the"/>
  <result pre="Severe acute respiratory syndrome Coronavirus disease 2019 1 Introduction Viral" exact="infectious diseases" post="have had a catastrophic impact in the past century."/>
  <result pre="A virus, claimed the lives of 50 million people. The" exact="acquired immunodeficiency syndrome" post="(AIDS) pandemic was started in the early 1980s, yet"/>
  <result pre="virus, claimed the lives of 50 million people. The acquired" exact="immunodeficiency" post="syndrome (AIDS) pandemic was started in the early 1980s,"/>
  <result pre="claimed the lives of 50 million people. The acquired immunodeficiency" exact="syndrome" post="(AIDS) pandemic was started in the early 1980s, yet"/>
  <result pre="yet over 37 million people are still living with the" exact="disease" post="in 2020 [200]. Health organizations have put together countless"/>
  <result pre="and detection strategies to combat the spread and re-emergence of" exact="viral" post="infectious diseases [1]. Despite these efforts, fighting viral diseases"/>
  <result pre="detection strategies to combat the spread and re-emergence of viral" exact="infectious diseases" post="[1]. Despite these efforts, fighting viral diseases has remained"/>
  <result pre="re-emergence of viral infectious diseases [1]. Despite these efforts, fighting" exact="viral" post="diseases has remained a formidable task. Presently, the coronavirus"/>
  <result pre="developed to target host cell receptors and/or stages of the" exact="viral" post="lifecycle. These antiviral agents can be divided into six"/>
  <result pre="be effective in reducing morbidity and mortality associated with the" exact="viral infection," post="the rapid mutation rate in the viral genome enables"/>
  <result pre="with the viral infection, the rapid mutation rate in the" exact="viral" post="genome enables viruses to quickly adapt and develop drug"/>
  <result pre="Moreover, peptides are employed in detection assays to diagnose various" exact="infectious diseases." post="Peptide-based diagnostic reagents are generally preferred due to their"/>
  <result pre="In this article, we provide an overview of the five" exact="infectious diseases;" post="influenza (flu), chronic hepatitis B (CHB), AIDS, severe acute"/>
  <result pre="provide an overview of the five infectious diseases; influenza (flu)," exact="chronic hepatitis" post="B (CHB), AIDS, severe acute respiratory syndrome (SARS), and"/>
  <result pre="an overview of the five infectious diseases; influenza (flu), chronic" exact="hepatitis" post="B (CHB), AIDS, severe acute respiratory syndrome (SARS), and"/>
  <result pre="infectious diseases; influenza (flu), chronic hepatitis B (CHB), AIDS, severe" exact="acute" post="respiratory syndrome (SARS), and COVID-19. The current FDA approved"/>
  <result pre="diseases; influenza (flu), chronic hepatitis B (CHB), AIDS, severe acute" exact="respiratory" post="syndrome (SARS), and COVID-19. The current FDA approved therapeutics"/>
  <result pre="influenza (flu), chronic hepatitis B (CHB), AIDS, severe acute respiratory" exact="syndrome" post="(SARS), and COVID-19. The current FDA approved therapeutics are"/>
  <result pre="COVID-19. The current FDA approved therapeutics are reviewed for each" exact="disease" post="and the applications of novel peptide-based agents are summarized."/>
  <result pre="2 . Fig. 2 Schematic of peptide applications in targeting" exact="viral" post="infectious diseases. Utilization of peptides as therapeutics, vaccines, or"/>
  <result pre=". Fig. 2 Schematic of peptide applications in targeting viral" exact="infectious diseases." post="Utilization of peptides as therapeutics, vaccines, or diagnostic reagents"/>
  <result pre="of peptides as therapeutics, vaccines, or diagnostic reagents to combat" exact="viral" post="diseases is illustrated here. 2 Influenza Influenza (flu), a"/>
  <result pre="is illustrated here. 2 Influenza Influenza (flu), a highly contagious" exact="respiratory" post="disease caused by influenza virus, is classified into three"/>
  <result pre="illustrated here. 2 Influenza Influenza (flu), a highly contagious respiratory" exact="disease" post="caused by influenza virus, is classified into three types:"/>
  <result pre="36 million illnesses during the 2018â€&quot;2019 flu season [30]. Two" exact="viral" post="capsid proteins, Hemagglutinin (HA) and Neuraminidase (NA) play key"/>
  <result pre="proteins, Hemagglutinin (HA) and Neuraminidase (NA) play key roles during" exact="viral infection" post="[82,187]. Based on the different combinations of HA and"/>
  <result pre="Hemagglutinin (HA) and Neuraminidase (NA) play key roles during viral" exact="infection" post="[82,187]. Based on the different combinations of HA and"/>
  <result pre="different groups and subtypes [31]. HA is presented on the" exact="viral" post="surface as a homotrimer composed of HA1 and HA2"/>
  <result pre="HA1 and HA2 subunits linked by a disulfide bond. The" exact="infection" post="event is triggered by HA1 binding to sialylated receptors"/>
  <result pre="by the interaction of matrix-2 (M2) ion channel with the" exact="viral" post="envelope and release of viral ribonucleoproteins (RNPs) and genome"/>
  <result pre="(M2) ion channel with the viral envelope and release of" exact="viral" post="ribonucleoproteins (RNPs) and genome into the host cell cytosol."/>
  <result pre="ribonucleoproteins (RNPs) and genome into the host cell cytosol. The" exact="viral" post="RNA is then replicated, translated, and assembled into viral"/>
  <result pre="The viral RNA is then replicated, translated, and assembled into" exact="viral" post="particles. Virus particles then leave the host cells by"/>
  <result pre="by budding out when NA cleaves sialic acid to enable" exact="viral" post="release [8]. Due to their critical functions, viral HA,"/>
  <result pre="to enable viral release [8]. Due to their critical functions," exact="viral" post="HA, NA, and M2 proteins have been the focus"/>
  <result pre="approved influenza therapeutics targeting M2 and NA proteins shorten the" exact="disease" post="time-course and reduce the severity of symptoms. Adamantane derivatives,"/>
  <result pre="B. Xofluza inhibits polymerase acidic endonuclease, an enzyme essential for" exact="viral" post="replication [112]. Favipiravir (Avigan), which also blocks viral replication"/>
  <result pre="essential for viral replication [112]. Favipiravir (Avigan), which also blocks" exact="viral" post="replication is approved for influenza in Japan [67] and"/>
  <result pre="a high rate of drug resistance [151]. In addition, resistant" exact="viral" post="mutants have shown decreased sensitivity to oseltamivir [28]. The"/>
  <result pre="defensins and cathelicidins, provide great starting scaffolds for drug development." exact="Mouse" post="Î²-defensin-4 (mBD4) has been shown to have antiviral activity"/>
  <result pre="the virus was shown to alter endosomal acidification and inhibit" exact="viral" post="RNA release and replication. Potent antiviral activities of P9"/>
  <result pre="Cathelicidin, another class of naturally occurring AMPs, can disrupt the" exact="viral" post="envelope to achieve potent antiviral activity. Tripathi and colleagues"/>
  <result pre="antiviral activity. Helical fragment of LL-37 showed greater activity in" exact="viral" post="reduction with H1N1 strain (IC50 3.2 Î¼M) than the"/>
  <result pre="milk was shown to bind to HA and inhibit the" exact="infection" post="of influenza subtypes H1N1 and H3N2. By molecular docking,"/>
  <result pre="the H5N1 subtype. EB (RRKKAAVALLPAVLLALLAP) bound specifically to HA, prevented" exact="viral" post="cell entry in the MDCK cell line, and had"/>
  <result pre="17â€&quot;37â€¯nM). P7 inhibited HA conformational rearrangement in the endosome, preventing" exact="viral" post="fusion with the host cell membrane [108]. In a"/>
  <result pre="with the host cell membrane [108]. In a parallel approach," exact="viral" post="proteins are used to develop anti-viral peptides. For example,"/>
  <result pre="interaction of sialylglyco-conjugate receptors on the host cell surface with" exact="viral" post="HA protein. Optimized f1 was an alkylated peptide (C-18-s2(1âˆ’5)"/>
  <result pre="peptide bound to NA with nanomolar affinity and inhibited H1N1" exact="infection" post="at Î¼M concentration in MDCK cells. Administration of the"/>
  <result pre="literature. The administration of influenza vaccines is recommended to prevent" exact="virus infection." post="During 2017â€&quot;2018, the influenza vaccination prevented 91,000 influenza-related hospitalizations"/>
  <result pre="challenging to predict epidemics due to the high diversity of" exact="viral" post="subtypes [29]. Next, we summarize a few peptide-based vaccines"/>
  <result pre="Multimeric-001 (M-001) is another peptide vaccine that has met its" exact="primary" post="endpoint in phase II. It consists of three repetitions"/>
  <result pre="B and T cell-specific immune responses and offers protection against" exact="infection" post="with different influenza strains, including H5N1 strain. M-001 is"/>
  <result pre="antibody-producing B cells, both of which can protect from severe" exact="disease" post="symptoms upon infection [90]. The currently used influenza diagnostic"/>
  <result pre="both of which can protect from severe disease symptoms upon" exact="infection" post="[90]. The currently used influenza diagnostic tests are based"/>
  <result pre="and differentiate influenza A and B viruses but have a" exact="limited" post="capability to identify subtypes of influenza A viruses. Therefore,"/>
  <result pre="a peptide-based molecular beacon (PEP-MB) for the detection of Influenza" exact="type A" post="using fluorescence resonance energy transfer (FRET). A HA1-specific binding"/>
  <result pre="a black hole quencher 2 (BHQ2)-modified oligonucleotide (Oligo-BHQ2). In the" exact="absence of" post="virus particles, PEP-MB constructs form hairpin structures that result"/>
  <result pre="PEP-MB undergoes a conformational change due to the binding to" exact="viral" post="HA. As a result, strong fluorescence is emitted and"/>
  <result pre="agglutination assay using red blood cells since it is more" exact="stable" post="with an extended storage period [136]. 3 Chronic hepatitis"/>
  <result pre="is more stable with an extended storage period [136]. 3" exact="Chronic" post="hepatitis B Chronic Hepatitis B (CHB) is caused by"/>
  <result pre="more stable with an extended storage period [136]. 3 Chronic" exact="hepatitis" post="B Chronic Hepatitis B (CHB) is caused by the"/>
  <result pre="with an extended storage period [136]. 3 Chronic hepatitis B" exact="Chronic" post="Hepatitis B (CHB) is caused by the hepadnavirus hepatitis"/>
  <result pre="an extended storage period [136]. 3 Chronic hepatitis B Chronic" exact="Hepatitis" post="B (CHB) is caused by the hepadnavirus hepatitis B"/>
  <result pre="B Chronic Hepatitis B (CHB) is caused by the hepadnavirus" exact="hepatitis" post="B virus (HBV), which targets the liver leading to"/>
  <result pre="that is coated with a lipid bilayer and packaged with" exact="viral" post="polymerase, relaxed circular DNA (rcDNA), and three types of"/>
  <result pre="into the host-specific covalently closed circular DNA (cccDNA) by the" exact="viral" post="polymerase, which plays a critical role in HBV replication"/>
  <result pre="and entecavir, which suppress polymerase activity, inhibit reverse transcription of" exact="viral" post="RNAs, and stop the synthesis of cccDNA; 2) stimulate"/>
  <result pre="is a peptide called PTD-p37 that was designed to inhibit" exact="viral" post="regeneration. The peptide contained an N-terminal cell-penetrating domain (YGRKKRRQRRR)"/>
  <result pre="levels are increased [113,120,170]. PTD-p37 treatment reduced HBsAg levels and" exact="viral" post="proliferation in vitro and in mice [170,61,125]. Peptides have"/>
  <result pre="mice [170,61,125]. Peptides have also demonstrated significant potential in interrupting" exact="virus infection" post="in preclinical research. HBsAg is composed of three types"/>
  <result pre="[170,61,125]. Peptides have also demonstrated significant potential in interrupting virus" exact="infection" post="in preclinical research. HBsAg is composed of three types"/>
  <result pre="(S) protein with S domain only. The pre-S1 domain initiates" exact="virus infection" post="by binding to the host receptor called sodium taurocholate"/>
  <result pre="protein with S domain only. The pre-S1 domain initiates virus" exact="infection" post="by binding to the host receptor called sodium taurocholate"/>
  <result pre="the low-affinity HBV co-receptor heparan sulfate proteoglycan (HSPG) [195,148,14]. Therefore" exact="viral" post="cell entry can be blocked by targeting host receptors,"/>
  <result pre="be blocked by targeting host receptors, NTCP and HSPG, or" exact="viral" post="antigen HBsAg. These approaches will be discussed next. Novel"/>
  <result pre="from pre-S1, Myrcludex-B, that binds to NTCP and inhibit HBV" exact="infection" post="in cell culture and animal models [203,76,159]. Liposomal formulation"/>
  <result pre="allows for oral administration and has been investigated as a" exact="hepatitis" post="B peptide drug in the clinic [199]. A Phase"/>
  <result pre="The five most potent drugs were tested in the HBV" exact="infection" post="assay using human hepatic cell line HepaRG. They are"/>
  <result pre="Blue 6B. All five drugs were shown to block HBV" exact="infection" post="at similar levels of potency. Although, Donker's unique approach"/>
  <result pre="The host receptor, HSPG binds to pre-S1 to initiate the" exact="viral" post="integration to host cells. This is followed by the"/>
  <result pre="pre-S1 were also investigated for the treatment of CHB. A" exact="short" post="peptide B10 (SGSGLRNIRST) was identified by the phage peptide"/>
  <result pre="The peptide disrupted the interaction of HBV with human hepatocyte" exact="carcinoma" post="cells [87]. B10 was optimized based on the key"/>
  <result pre="(28â€&quot;42) of HBV. Peptide 4B10 was shown to inhibit HBV" exact="infection" post="in both primary tupaia and human hepatocytes [225,71]. In"/>
  <result pre="Peptide 4B10 was shown to inhibit HBV infection in both" exact="primary" post="tupaia and human hepatocytes [225,71]. In a separate study,"/>
  <result pre="novel membrane and extracellular proteins that are involved in HBV" exact="infection" post="such as lipoprotein lipase [50]. In addition to targeting"/>
  <result pre="patients, vaccine-based therapies can help restore the immune response for" exact="viral" post="elimination [142]. A pilot study of a peptide-based T"/>
  <result pre="CY-1899 failed to induce vigorous cytotoxic T lymphocyte activity or" exact="viral" post="clearance possibly due to T-cell exhaustion in CHB patients"/>
  <result pre="patients [56,19,115]. Peptide-based vaccines have been developed to prevent HBV" exact="infection" post="in healthy individuals. It should be noted that in"/>
  <result pre="antibody production in rabbits and cynomolgus monkeys [229]. A grass" exact="pollen allergy" post="vaccine, BM32, containing a pre-S domain (pre-S1 and pre-S2)"/>
  <result pre="production in rabbits and cynomolgus monkeys [229]. A grass pollen" exact="allergy" post="vaccine, BM32, containing a pre-S domain (pre-S1 and pre-S2)"/>
  <result pre="inducing IgG antibodies against HBV. BM32 also protected rabbits from" exact="HIV infection" post="as effectively as the approved vaccine Engerix-B [43]. Immunoinformatic"/>
  <result pre="IgG antibodies against HBV. BM32 also protected rabbits from HIV" exact="infection" post="as effectively as the approved vaccine Engerix-B [43]. Immunoinformatic"/>
  <result pre="bioinformatic tools have been employed to develop peptide-based vaccines for" exact="hepatitis" post="B and might hold potentials in future pre-clinical studies"/>
  <result pre="for binding to the anti-hepatitis B core antibody [48]. 4" exact="Acquired" post="immunodeficiency syndrome Acquired Immunodeficiency Syndrome (AIDS) is a disease"/>
  <result pre="binding to the anti-hepatitis B core antibody [48]. 4 Acquired" exact="immunodeficiency" post="syndrome Acquired Immunodeficiency Syndrome (AIDS) is a disease caused"/>
  <result pre="to the anti-hepatitis B core antibody [48]. 4 Acquired immunodeficiency" exact="syndrome" post="Acquired Immunodeficiency Syndrome (AIDS) is a disease caused by"/>
  <result pre="the anti-hepatitis B core antibody [48]. 4 Acquired immunodeficiency syndrome" exact="Acquired Immunodeficiency Syndrome" post="(AIDS) is a disease caused by human immunodeficiency virus"/>
  <result pre="anti-hepatitis B core antibody [48]. 4 Acquired immunodeficiency syndrome Acquired" exact="Immunodeficiency Syndrome" post="(AIDS) is a disease caused by human immunodeficiency virus"/>
  <result pre="B core antibody [48]. 4 Acquired immunodeficiency syndrome Acquired Immunodeficiency" exact="Syndrome" post="(AIDS) is a disease caused by human immunodeficiency virus"/>
  <result pre="4 Acquired immunodeficiency syndrome Acquired Immunodeficiency Syndrome (AIDS) is a" exact="disease" post="caused by human immunodeficiency virus (HIV). HIV can directly"/>
  <result pre="Acquired Immunodeficiency Syndrome (AIDS) is a disease caused by human" exact="immunodeficiency" post="virus (HIV). HIV can directly weaken the immune system"/>
  <result pre="immune system and make it vulnerable to other pathogens. The" exact="viral" post="envelope (Env) protein is a key driver of the"/>
  <result pre="viral envelope (Env) protein is a key driver of the" exact="viral" post="binding and fusion to the target cells and contains"/>
  <result pre="gp120 and transmembrane gp41. These glycoproteins surround the nucleocapsid containing" exact="viral" post="RNA and reverse transcriptase. The binding of viral gp120"/>
  <result pre="nucleocapsid containing viral RNA and reverse transcriptase. The binding of" exact="viral" post="gp120 to the CD4 receptor exposes its binding site"/>
  <result pre="change to form a six-helical bundle (6HB). The 6HB initiates" exact="viral" post="entry by triggering the insertion of the fusion peptide"/>
  <result pre="of gp41) into the host cell membrane [220,16,32]. Ultimately, the" exact="viral" post="and host membrane fuse together followed by the insertion"/>
  <result pre="and host membrane fuse together followed by the insertion of" exact="viral" post="genetic material in the cytosol. The viral RNA is"/>
  <result pre="the insertion of viral genetic material in the cytosol. The" exact="viral" post="RNA is transcribed to dsDNA. Integrase then carries dsDNA"/>
  <result pre="inserts it into the host chromosome causing lifelong infection. The" exact="viral" post="DNA is replicated, translated, and assembled at the cell"/>
  <result pre="as an immature polypeptide chain, which is cleaved by the" exact="viral" post="proteases to form mature infectious virion [66]. Most of"/>
  <result pre="which is cleaved by the viral proteases to form mature" exact="infectious" post="virion [66]. Most of the FDA approved anti-HIV drugs"/>
  <result pre="virion [66]. Most of the FDA approved anti-HIV drugs target" exact="viral" post="reverse transcription factor, proteases, integrases, and structural proteins to"/>
  <result pre="Pre-clinical [147] FB006M Ac-WEEWDREINNYTK (MPA)LIHELIEESQNQQEKNEQELL-CONH2 Gp41 CHR Gp41 NHR 2.7" exact="peripheral" post="blood mononuclear cell (PBMC) assay, ELISA Approved [222] CP32M"/>
  <result pre="act as the first line of defense to protect against" exact="HIV infection." post="AMPs from bacteria, plants, animals, and humans have been"/>
  <result pre="CHR and prevents the formation of 6HB. As a result," exact="viral" post="fusion to host cells is inhibited [104,211]. This peptide"/>
  <result pre="peptide derived from HIV-2 helical region 2 of gp41that blocks" exact="HIV infection" post="at a sub-nanomolar concentration in both HIV-1 and HIV-2"/>
  <result pre="derived from HIV-2 helical region 2 of gp41that blocks HIV" exact="infection" post="at a sub-nanomolar concentration in both HIV-1 and HIV-2"/>
  <result pre="infection at a sub-nanomolar concentration in both HIV-1 and HIV-2" exact="primary" post="isolates [21]. It was suggested that the alpha-helical structure"/>
  <result pre="approaches, targets the conserved pocket region of gp41 and prevents" exact="viral" post="fusion to host cells. LP-19 with a membrane-anchoring lipid"/>
  <result pre="LP-19 exhibited extended half-life in rhesus macaques and drastically reduced" exact="viral" post="loads in infected monkeys [38]. Peptides derived from viral"/>
  <result pre="reduced viral loads in infected monkeys [38]. Peptides derived from" exact="viral" post="sequences, including gp41 can be potentially immunogenic. However, it"/>
  <result pre="gp41 can be potentially immunogenic. However, it is possible to" exact="lower" post="the immunogenicity risk through peptide engineering. The novel HIV"/>
  <result pre="and improved its antiviral activity profile. V2o efficiently inhibited the" exact="viral" post="entry in PM-1 cells infected with lentiviral vector particles"/>
  <result pre="that peptides derived from host cells that are involved in" exact="viral infection" post="have also been considered. An example is peptide 2C"/>
  <result pre="peptides derived from host cells that are involved in viral" exact="infection" post="have also been considered. An example is peptide 2C"/>
  <result pre="years of effort, there is no available vaccine to prevent" exact="HIV infection" post="and progression. Most vaccines that have been developed have"/>
  <result pre="of effort, there is no available vaccine to prevent HIV" exact="infection" post="and progression. Most vaccines that have been developed have"/>
  <result pre="have failed to induce a protective immune response against HIV-1" exact="infection" post="in clinical trials. Eliciting neutralizing antibodies using gp120 as"/>
  <result pre="the loops of gp120, a minimal epitope derived from the" exact="external" post="region of gp41 (EC26-2A4Î&quot;M: ELLELDKM) has also shown potential"/>
  <result pre="at high levels during the early and late stages of" exact="HIV infection." post="In REDUC clinical study, administration of Vacc-4x as part"/>
  <result pre="role in developing HIV diagnostic reagents. The US Centers for" exact="Disease" post="Control and Prevention (CDC) recommends two types of diagnostic"/>
  <result pre="detection and HIV-1 and HIV-2 antibody test for early to" exact="chronic" post="stage detection. Commonly used HIV tests range from immunofluorescence"/>
  <result pre="anti-p24 antibodies [70] and a bifunctional colorimetric/fluorescence assay that uses" exact="short" post="peptides derived from HIV-1 p17 protein tagged to a"/>
  <result pre="detect the majority of anti-HIV-antibodies in biological samples [132]. 5" exact="Severe" post="acute respiratory syndrome Severe acute respiratory syndrome (SARS) is"/>
  <result pre="the majority of anti-HIV-antibodies in biological samples [132]. 5 Severe" exact="acute" post="respiratory syndrome Severe acute respiratory syndrome (SARS) is caused"/>
  <result pre="majority of anti-HIV-antibodies in biological samples [132]. 5 Severe acute" exact="respiratory" post="syndrome Severe acute respiratory syndrome (SARS) is caused by"/>
  <result pre="of anti-HIV-antibodies in biological samples [132]. 5 Severe acute respiratory" exact="syndrome" post="Severe acute respiratory syndrome (SARS) is caused by SARS"/>
  <result pre="anti-HIV-antibodies in biological samples [132]. 5 Severe acute respiratory syndrome" exact="Severe" post="acute respiratory syndrome (SARS) is caused by SARS coronavirus"/>
  <result pre="in biological samples [132]. 5 Severe acute respiratory syndrome Severe" exact="acute" post="respiratory syndrome (SARS) is caused by SARS coronavirus 1"/>
  <result pre="biological samples [132]. 5 Severe acute respiratory syndrome Severe acute" exact="respiratory" post="syndrome (SARS) is caused by SARS coronavirus 1 (SARS-CoV-1),"/>
  <result pre="samples [132]. 5 Severe acute respiratory syndrome Severe acute respiratory" exact="syndrome" post="(SARS) is caused by SARS coronavirus 1 (SARS-CoV-1), a"/>
  <result pre="that contain 16 non-structural proteins (nsp1 through nsp16) required for" exact="viral" post="replication and transcription. The polyproteins are cleaved into individual"/>
  <result pre="protease (3CLpro or Mpro) [189]. The structural region encodes four" exact="primary" post="structural proteins; spike protein (S), envelope protein (E), membrane"/>
  <result pre="innate immune response with unknown or poorly understood function. The" exact="viral infection" post="begins when the S protein binds to the host"/>
  <result pre="immune response with unknown or poorly understood function. The viral" exact="infection" post="begins when the S protein binds to the host"/>
  <result pre="angiotensin-converting enzyme 2 (ACE2). This allows cellular entry where the" exact="viral" post="RNA genome is released, transcribed, and translated. The newly"/>
  <result pre="RNA genome is released, transcribed, and translated. The newly formed" exact="viral" post="proteins and genomic RNA assemble in the endoplasmic reticulum-golgi"/>
  <result pre="viral proteins and genomic RNA assemble in the endoplasmic reticulum-golgi" exact="intermediate" post="compartment and fuse to the plasma membrane releasing the"/>
  <result pre="SARS occurred in southern China in November 2002 [49]. The" exact="disease" post="spread to more than 30 countries, infected over 8000"/>
  <result pre="controlled in less than four months through the measures of" exact="infection" post="control instead of drug prevention or therapy [214]. During"/>
  <result pre="the SARS outbreak, ribavirin was most frequently used to inhibit" exact="viral" post="RNA synthesis [74]. Ribavirin is a guanosine analog that"/>
  <result pre="Ribavirin is a guanosine analog that inhibits guanosine-triphosphate (GTP) synthesis," exact="viral" post="mRNA capping, and viral RNA-dependent RNA polymerase [49,20]. At"/>
  <result pre="analog that inhibits guanosine-triphosphate (GTP) synthesis, viral mRNA capping, and" exact="viral" post="RNA-dependent RNA polymerase [49,20]. At the time, ribavirin was"/>
  <result pre="RNA polymerase [49,20]. At the time, ribavirin was used for" exact="Hepatitis" post="C virus (HCV) therapy [233] and pediatric respiratory syncytial"/>
  <result pre="used for Hepatitis C virus (HCV) therapy [233] and pediatric" exact="respiratory" post="syncytial viral (RSV) infection [42]. The reported uses of"/>
  <result pre="Hepatitis C virus (HCV) therapy [233] and pediatric respiratory syncytial" exact="viral" post="(RSV) infection [42]. The reported uses of ribavirin in"/>
  <result pre="virus (HCV) therapy [233] and pediatric respiratory syncytial viral (RSV)" exact="infection" post="[42]. The reported uses of ribavirin in SARS cases"/>
  <result pre="peptides (P8: PSSKRFQPFQQFGRDVSDFT and P9: CANLLLQYGSFCTQLNRALSGIA) blocked the interaction of" exact="viral" post="S protein with the host ACE2 receptor and showed"/>
  <result pre="S protein with the host ACE2 receptor and showed promising" exact="viral" post="neutralization in syncytia formation models at nearly 50 %"/>
  <result pre="antiviral effects in cytopathic effect (CPE)-based assays, a reduction in" exact="viral" post="titer in TCID50 assays, as well as a reduction"/>
  <result pre="in TCID50 assays, as well as a reduction in intracellular" exact="viral" post="RNA levels as determined by quantitative real-time PCR (qRT-PCR)."/>
  <result pre="P8 were further confirmed by electron microscopy, which showed the" exact="absence of" post="virus in the P8-treated cells and the presence of"/>
  <result pre="plaque formation of SARS-CoV in Vero E6 cells [95]. Additional" exact="viral" post="structural proteins have been studied as potential targets. N"/>
  <result pre="N protein from the nucleocapsid forms a complex with the" exact="viral" post="RNA [128]. A 15-mer peptide phage display library was"/>
  <result pre="appeared at the highest frequency among the selected peptides. Targeting" exact="viral" post="proteases has been exploited for peptide antiviral drug therapies."/>
  <result pre="used to identify an octapeptide AVLQSGFR that docked to the" exact="viral" post="Mpro protease [39,59]. The peptide acted as an enzyme"/>
  <result pre="peptide P9 (NGAICWGPCPTAFRQIGNCGHFKVRCCKIR), mentioned earlier, exhibits antiviral effects against multiple" exact="respiratory" post="viruses including influenza viruses and SARS-CoV-1. By binding to"/>
  <result pre="viruses including influenza viruses and SARS-CoV-1. By binding to the" exact="viral" post="glycoprotein, P9 was able to alter endosomal acidification, block"/>
  <result pre="viral glycoprotein, P9 was able to alter endosomal acidification, block" exact="viral" post="membrane fusion, and RNA viral release [231]. P9 showed"/>
  <result pre="to alter endosomal acidification, block viral membrane fusion, and RNA" exact="viral" post="release [231]. P9 showed efficacy in cell-based assays and"/>
  <result pre="viral release [231]. P9 showed efficacy in cell-based assays and" exact="viral" post="load reduction in small animal models when used as"/>
  <result pre="in the literature. SARS-CoV-1 vaccines can be used to prevent" exact="viral infection" post="and transmission thereby aid in the control of outbreaks."/>
  <result pre="the literature. SARS-CoV-1 vaccines can be used to prevent viral" exact="infection" post="and transmission thereby aid in the control of outbreaks."/>
  <result pre="the promising safety results, these candidate vaccines induced an immunopathologic" exact="respiratory" post="disease in small animal studies when the immunized mice"/>
  <result pre="promising safety results, these candidate vaccines induced an immunopathologic respiratory" exact="disease" post="in small animal studies when the immunized mice were"/>
  <result pre="but not with control serum samples from healthy donors or" exact="hepatitis" post="patients. This approach was shown to be effective to"/>
  <result pre="the N protein to induce an immune response. Currently, SARS-CoV-1" exact="infection" post="is diagnosed by detection of viral RNA in clinical"/>
  <result pre="immune response. Currently, SARS-CoV-1 infection is diagnosed by detection of" exact="viral" post="RNA in clinical samples by qRT-PCR, serological detection of"/>
  <result pre="necessary to prevent a likely future pandemic [94,150,105]. 6 Coronavirus" exact="disease" post="2019 Coronavirus disease 2019 (COVID-19) is a novel infectious"/>
  <result pre="a likely future pandemic [94,150,105]. 6 Coronavirus disease 2019 Coronavirus" exact="disease" post="2019 (COVID-19) is a novel infectious disease caused by"/>
  <result pre="Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) is a novel" exact="infectious disease" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."/>
  <result pre="disease 2019 Coronavirus disease 2019 (COVID-19) is a novel infectious" exact="disease" post="caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."/>
  <result pre="2019 (COVID-19) is a novel infectious disease caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus shares 79"/>
  <result pre="(COVID-19) is a novel infectious disease caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). The virus shares 79 %"/>
  <result pre="is a novel infectious disease caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). The virus shares 79 % genetic"/>
  <result pre="FDA approved vaccines or antivirals were available to combat the" exact="disease" post="[188]. With an immediate need for COVID-19 therapies, attention"/>
  <result pre="created an extensive overview of notable published scientific articles, key" exact="viral" post="target proteins, existing drugs with potential therapeutic use, select"/>
  <result pre="protein-protein interaction between the virus and host receptor and prevents" exact="viral" post="cell entry. SBP1 (IEEQAKTFLDKFNHEAEDLFYQS) was derived from Î±1 helix"/>
  <result pre="each other to form a 6HB fusion core bringing the" exact="viral" post="and host membrane in close proximity for fusion. EK1"/>
  <result pre="fusion. EK1 peptide binds to the HR1 domain inhibiting the" exact="viral infection" post="as shown in S-mediated cell-cell fusion assays [221]. A"/>
  <result pre="EK1 peptide binds to the HR1 domain inhibiting the viral" exact="infection" post="as shown in S-mediated cell-cell fusion assays [221]. A"/>
  <result pre="protons in the endosome to inhibit endosomal acidification, thereby preventing" exact="viral" post="RNA release. P9R showed 1000-fold enhanced potency compared to"/>
  <result pre="vaccine developments include RNA vaccines, DNA vaccines, recombinant protein vaccines," exact="viral" post="vector-based vaccines, live attenuated vaccines, and inactivated vaccines [6]."/>
  <result pre="aforementioned mRNA vaccines encode for the SARS-CoV-2 S proteins, other" exact="viral" post="recombinant proteins are being investigated [126]. One group has"/>
  <result pre="Current laboratory tests for SARS-CoV-2 diagnostics involve the detection of" exact="viral" post="RNA by qRT-PCR and the detection of anti-SARS-CoV-2 antibodies"/>
  <result pre="accuracy of 71.4 % and 57.2 %, respectively. 7 Conclusion" exact="Infectious" post="diseases are an ongoing global health concern with a"/>
  <result pre="vaccines in early-development and their application in the diagnosis of" exact="viral" post="infections. Peptide-based therapeutics hold great promises as a novel"/>
  <result pre="However, the use of naturally and synthetically derived peptides is" exact="limited" post="by their short in vivo half-lives caused by proteolysis"/>
  <result pre="of naturally and synthetically derived peptides is limited by their" exact="short" post="in vivo half-lives caused by proteolysis and renal clearance."/>
  <result pre="use of whole organisms or proteins, such as allergic and" exact="autoimmune" post="responses. However, low immunogenicity can be a limiting factor"/>
  <result pre="been used in innovative technologies, such as biosensors, to diagnose" exact="viral" post="infections. Overall, as discussed herein, peptides can be used"/>
  <result pre="discussed herein, peptides can be used to help combat different" exact="viral" post="diseases. Funding Eurofins Lancaster Laboratories provided support in the"/>
  <result pre="authors report no declarations of interest. References References 1Preventing emerging" exact="infectious" post="diseases: a strategy for the 21st century. Overview of"/>
  <result pre="Av. Bioinformatics Tool For Allergenicity Prediction2020http://www.ddg-pharmfac.net/AllerTOP/index.html 5AlghrairZ.K.FernigD.G.EbrahimiB.Enhanced inhibition of influenza" exact="virus infection" post="by peptide-noble-metal nanoparticle conjugatesBeilstein J. Nanotechnol.1020191038104731165030 6AmanatF.KrammerF.SARS-CoV-2 vaccines: status"/>
  <result pre="Bioinformatics Tool For Allergenicity Prediction2020http://www.ddg-pharmfac.net/AllerTOP/index.html 5AlghrairZ.K.FernigD.G.EbrahimiB.Enhanced inhibition of influenza virus" exact="infection" post="by peptide-noble-metal nanoparticle conjugatesBeilstein J. Nanotechnol.1020191038104731165030 6AmanatF.KrammerF.SARS-CoV-2 vaccines: status"/>
  <result pre="virusPathog. Glob. Health10612012121922595270 8Arbeitskreis BlutU.Influenza virusTransfus Med. Hemother.3612009323921048819 9YsrafilAstuti I.Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral"/>
  <result pre="Glob. Health10612012121922595270 8Arbeitskreis BlutU.Influenza virusTransfus Med. Hemother.3612009323921048819 9YsrafilAstuti I.Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure"/>
  <result pre="Health10612012121922595270 8Arbeitskreis BlutU.Influenza virusTransfus Med. Hemother.3612009323921048819 9YsrafilAstuti I.Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): an overview of viral structure and"/>
  <result pre="I.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of" exact="viral" post="structure and host responseDiabetes Metab. Syndr.144202040741232335367 10AtsmonJ.CaracoY.Ziv-SeferS.ShaikevichD.AbramovE.VolokhovI.Priming by a"/>
  <result pre="(APPROACH) and in rhesus monkeys (NHP 13-19)Lancet39210143201823224330047376 14BarreraA.GuerraB.NotvallL.LanfordR.E.Mapping of the" exact="hepatitis" post="B virus pre-S1 domain involved in receptor recognitionJ. Virol.791520059786979816014940"/>
  <result pre="in womenPLoS One1342018e0195744 16BergerE.A.MurphyP.M.FarberJ.M.Chemokine receptors as HIV-1 coreceptors: roles in" exact="viral" post="entry, tropism, and diseaseAnnu. Rev. Immunol.17199965770010358771 17BioinformaticsD.NetCTL 1.2 Server2017"/>
  <result pre="1.2 Server2017 18BobykK.D.MandadapuS.R.LohithK.GuzzoC.BhargavaA.LussoP.Design of HIV coreceptor derived peptides that inhibit" exact="viral" post="entry at submicromolar concentrationsMol. Pharm.14820172681268928494151 19BoniC.FisicaroP.ValdattaC.AmadeiB.Di VincenzoP.GiubertiT.Characterization of hepatitis"/>
  <result pre="inhibit viral entry at submicromolar concentrationsMol. Pharm.14820172681268928494151 19BoniC.FisicaroP.ValdattaC.AmadeiB.Di VincenzoP.GiubertiT.Characterization of" exact="hepatitis" post="B virus (HBV)-specific T-cell dysfunction in chronic HBV infectionJ."/>
  <result pre="19BoniC.FisicaroP.ValdattaC.AmadeiB.Di VincenzoP.GiubertiT.Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in" exact="chronic" post="HBV infectionJ. Virol.81820074215422517287266 20BoothC.M.MatukasL.M.TomlinsonG.A.RachlisA.R.RoseD.B.DwoshH.A.Clinical features and short-term outcomes of"/>
  <result pre="with SARS in the greater Toronto areaJAMA2892120032801280912734147 21BorregoP.CaladoR.MarcelinoJ.M.PereiraP.QuintasA.BarrosoH.An ancestral HIV-2/simian" exact="immunodeficiency" post="virus peptide with potent HIV-1 and HIV-2 fusion inhibitor"/>
  <result pre="Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona" exact="Virus Disease" post="2019 (COVID-19) medRxiv2020 26CaoP.DouG.ChengY.CheJ.The improved efficacy of sifuvirtide compared"/>
  <result pre="Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Corona Virus" exact="Disease" post="2019 (COVID-19) medRxiv2020 26CaoP.DouG.ChengY.CheJ.The improved efficacy of sifuvirtide compared"/>
  <result pre="of the receptor binding of 2019-nCoVBiochem. Biophys. Res. Commun.2020 36ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
  <result pre="the receptor binding of 2019-nCoVBiochem. Biophys. Res. Commun.2020 36ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
  <result pre="receptor binding of 2019-nCoVBiochem. Biophys. Res. Commun.2020 36ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infectionClin."/>
  <result pre="silico prediction of human leukocytes antigen (HLA) class II binding" exact="hepatitis" post="B virus (HBV) peptides in BotswanaViruses1272020 38ChongH.XueJ.XiongS.CongZ.DingX.ZhuY.A lipopeptide HIV-1/2"/>
  <result pre="against SARSBiochem. Biophys. Res. Commun.3081200314815112890493 40CimbroR.PetersonF.C.LiuQ.GuzzoC.ZhangP.MiaoH.Tyrosine-sulfated V2 peptides inhibit HIV-1" exact="infection" post="via coreceptor mimicryEBioMedicine102016455427389109 41ConlonJ.M.MechkarskaM.LukicM.L.FlattP.R.Potential therapeutic applications of multifunctional host-defense"/>
  <result pre="anti-viral, immunomodulatory, and anti-diabetic agentsPeptides572014677724793775 42CooperA.C.BanasiakN.C.AllenP.J.Management and prevention strategies for" exact="respiratory" post="syncytial virus (RSV) bronchiolitis in infants and young children:"/>
  <result pre="agentsPeptides572014677724793775 42CooperA.C.BanasiakN.C.AllenP.J.Management and prevention strategies for respiratory syncytial virus (RSV)" exact="bronchiolitis" post="in infants and young children: a review of evidence-based"/>
  <result pre="of evidence-based practice interventionsPediatr. Nurs.296200345245614743842 43CorneliusC.SchÃ¶neweisK.GeorgiF.WeberM.NiederbergerV.ZieglmayerP.Immunotherapy with the PreS-based grass" exact="pollen allergy" post="vaccine BM32 induces antibody responses protecting against hepatitis B"/>
  <result pre="evidence-based practice interventionsPediatr. Nurs.296200345245614743842 43CorneliusC.SchÃ¶neweisK.GeorgiF.WeberM.NiederbergerV.ZieglmayerP.Immunotherapy with the PreS-based grass pollen" exact="allergy" post="vaccine BM32 induces antibody responses protecting against hepatitis B"/>
  <result pre="grass pollen allergy vaccine BM32 induces antibody responses protecting against" exact="hepatitis" post="B infectionEBioMedicine112016586727568223 44CottenS.W.ZouJ.WangR.HuangB.C.LiuR.mRNA display-based selections using synthetic peptide and"/>
  <result pre="and natural protein librariesMethods Mol. Biol.805201228729722094812 45CraxiA.Di BonaD.CammaC.Interferon-alpha for HBeAg-positive" exact="chronic hepatitis" post="BJ. Hepatol.39Suppl 12003S9910514708686 46GordonDavid E.GMJKroganNevan J.A SARS-CoV-2 protein interaction"/>
  <result pre="natural protein librariesMethods Mol. Biol.805201228729722094812 45CraxiA.Di BonaD.CammaC.Interferon-alpha for HBeAg-positive chronic" exact="hepatitis" post="BJ. Hepatol.39Suppl 12003S9910514708686 46GordonDavid E.GMJKroganNevan J.A SARS-CoV-2 protein interaction"/>
  <result pre="Ther.42200629130216597209 48de SouzaM.Q.GaldinoA.S.dos SantosJ.C.SoaresM.V.de NobregaY.C.Alvares AdaC.A recombinant multiepitope protein for" exact="hepatitis" post="B diagnosisBiomed Res. Int.20132013148317 49de WitE.van DoremalenN.FalzaranoD.MunsterV.J.SARS and MERS:"/>
  <result pre="Rev. Microbiol.148201652353427344959 50DengQ.ZhaiJ.W.MichelM.L.ZhangJ.QinJ.KongY.Y.Identification and characterization of peptides that interact with" exact="hepatitis" post="B virus via the putative receptor binding siteJ. Virol.81820074244425417192308"/>
  <result pre="Soc.2352020e25506 52Dogo-IsonagieC.LamS.GustchinaE.AcharyaP.YangY.Shahzad-ul-HussanS.Peptides from second extracellular loop of C-C chemokine receptor" exact="type 5" post="(CCR5) inhibit diverse strains of HIV-1J. Biol. Chem.287182012150761508622403408 53DonkersJ.M.ZehnderB.van"/>
  <result pre="inhibit diverse strains of HIV-1J. Biol. Chem.287182012150761508622403408 53DonkersJ.M.ZehnderB.van WestenG.J.P.KwakkenbosM.J.API.J.Oude ElferinkR.P.J.Reduced" exact="hepatitis" post="B and D viral entry using clinically applied drugs"/>
  <result pre="HIV-1J. Biol. Chem.287182012150761508622403408 53DonkersJ.M.ZehnderB.van WestenG.J.P.KwakkenbosM.J.API.J.Oude ElferinkR.P.J.Reduced hepatitis B and D" exact="viral" post="entry using clinically applied drugs as novel inhibitors of"/>
  <result pre="selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human" exact="immunodeficiency" post="virus type 1 activityAntimicrob. Agents Chemother.491120054721473216251317 55DossM.RuchalaP.TecleT.GantzD.VermaA.HartshornA.Hapivirins and diprovirins:"/>
  <result pre="inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus" exact="type 1" post="activityAntimicrob. Agents Chemother.491120054721473216251317 55DossM.RuchalaP.TecleT.GantzD.VermaA.HartshornA.Hapivirins and diprovirins: novel Î¸-defensin analogs"/>
  <result pre="long peptide can boost CD4+ and CD8+ T-cell responses in" exact="chronic" post="HBV patients Ex vivoJ. Infect. Dis.2175201882783929220492 57DoytchinovaI.A.FlowerD.R.VaxiJen: a server"/>
  <result pre="der WerfS.BrodtH.R.BeckerS.Identification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN. Engl. J. Med.3482020031967197612690091 59DuQ.S.WangS.Q.ZhuY.WeiD.Q.GuoH.SiroisS.Polyprotein cleavage mechanism of"/>
  <result pre="WerfS.BrodtH.R.BeckerS.Identification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN. Engl. J. Med.3482020031967197612690091 59DuQ.S.WangS.Q.ZhuY.WeiD.Q.GuoH.SiroisS.Polyprotein cleavage mechanism of SARS"/>
  <result pre="modification of the octapeptidePeptides251120041857186415501516 60EdaY.TakizawaM.MurakamiT.MaedaH.KimachiK.YonemuraH.Sequential immunization with V3 peptides from" exact="primary" post="human immunodeficiency virus type 1 produces cross-neutralizing antibodies against"/>
  <result pre="the octapeptidePeptides251120041857186415501516 60EdaY.TakizawaM.MurakamiT.MaedaH.KimachiK.YonemuraH.Sequential immunization with V3 peptides from primary human" exact="immunodeficiency" post="virus type 1 produces cross-neutralizing antibodies against primary isolates"/>
  <result pre="60EdaY.TakizawaM.MurakamiT.MaedaH.KimachiK.YonemuraH.Sequential immunization with V3 peptides from primary human immunodeficiency virus" exact="type 1" post="produces cross-neutralizing antibodies against primary isolates with a matching"/>
  <result pre="primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against" exact="primary" post="isolates with a matching narrow-neutralization sequence motifJ. Virol.801120065552556216699036 61FanH.YanX.ZhangY.ZhangX.GaoY.XuY.Increased"/>
  <result pre="61FanH.YanX.ZhangY.ZhangX.GaoY.XuY.Increased expression of Gp96 by HBx-induced NF-kappaB activation feedback enhances" exact="hepatitis" post="B virus productionPLoS One862013e65588 62FehrA.R.PerlmanS.Coronaviruses: an overview of their"/>
  <result pre="prevent relapse after discontinuation of analogues in the treatment of" exact="chronic hepatitis" post="B: a randomised trial--ANRS HB02 VAC-ADNGut641201513914724555998 66FrankelA.D.YoungJ.A.HIV-1: fifteen proteins"/>
  <result pre="relapse after discontinuation of analogues in the treatment of chronic" exact="hepatitis" post="B: a randomised trial--ANRS HB02 VAC-ADNGut641201513914724555998 66FrankelA.D.YoungJ.A.HIV-1: fifteen proteins"/>
  <result pre="RNAAnnu. Rev. Biochem6719981259759480 67FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B Phys. Biol. Sci.9372017449463"/>
  <result pre="biosensing platform for HIV detectionChem. Commun. (Camb.)463201039539720066303 71GlebeD.UrbanS.KnoopE.V.CagN.KrassP.GrunS.Mapping of the" exact="hepatitis" post="B virus attachment site by use of infection-inhibiting preS1"/>
  <result pre="life cycle and novel drug targetsHepatol. Int.52201164465321484123 76GriponP.CannieI.UrbanS.Efficient inhibition of" exact="hepatitis" post="B virus infection by acylated peptides derived from the"/>
  <result pre="and novel drug targetsHepatol. Int.52201164465321484123 76GriponP.CannieI.UrbanS.Efficient inhibition of hepatitis B" exact="virus infection" post="by acylated peptides derived from the large viral surface"/>
  <result pre="novel drug targetsHepatol. Int.52201164465321484123 76GriponP.CannieI.UrbanS.Efficient inhibition of hepatitis B virus" exact="infection" post="by acylated peptides derived from the large viral surface"/>
  <result pre="B virus infection by acylated peptides derived from the large" exact="viral" post="surface proteinJ. Virol.79320051613162215650187 77GroÃŸA.HashimotoC.StichtH.EichlerJ.Synthetic peptides as protein mimicsFront. Bioeng."/>
  <result pre="Peptides2020http://imed.med.ucm.es/Tools/antigenic.pl 80GuanY.PeirisJ.S.ZhengB.PoonL.L.ChanK.H.ZengF.Y.Molecular epidemiology of the novel coronavirus that causes severe" exact="acute" post="respiratory syndromeLancet363940320049910414726162 81GuptaS.KapoorP.ChaudharyK.GautamA.KumarR.Open source drug Discovery C, et al."/>
  <result pre="80GuanY.PeirisJ.S.ZhengB.PoonL.L.ChanK.H.ZengF.Y.Molecular epidemiology of the novel coronavirus that causes severe acute" exact="respiratory" post="syndromeLancet363940320049910414726162 81GuptaS.KapoorP.ChaudharyK.GautamA.KumarR.Open source drug Discovery C, et al. In"/>
  <result pre="peripherally functionalized with hemagglutinin-binding peptideJ. Med. Chem.572020148332833925249262 84HayesC.N.ZhangY.MakokhaG.N.HasanM.Z.OmokokoM.D.ChayamaK.Early events in" exact="hepatitis" post="B virus infection: from the cell surface to the"/>
  <result pre="88HeY.ZhouY.WuH.LuoB.ChenJ.LiW.Identification of immunodominant sites on the spike protein of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics"/>
  <result pre="of immunodominant sites on the spike protein of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus: implication for developing SARS diagnostics and"/>
  <result pre="immunodominant sites on the spike protein of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus: implication for developing SARS diagnostics and vaccinesJ."/>
  <result pre="of the CY-1899 T-cell vaccine in subjects chronically infected with" exact="hepatitis" post="B virus. The CY1899 T cell vaccine study groupHepatology302199953153610421664"/>
  <result pre="incidentsNat. Rev. Microbiol.38200559160016064053 93HsiehI.N.HartshornK.L.The role of antimicrobial peptides in influenza" exact="virus infection" post="and their potential as antiviral and immunomodulatory therapyPharmaceuticals (Basel)932016"/>
  <result pre="Rev. Microbiol.38200559160016064053 93HsiehI.N.HartshornK.L.The role of antimicrobial peptides in influenza virus" exact="infection" post="and their potential as antiviral and immunomodulatory therapyPharmaceuticals (Basel)932016"/>
  <result pre="identification of linear B-cell epitopes and entry-blocking peptide of severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide libraryJ."/>
  <result pre="of linear B-cell epitopes and entry-blocking peptide of severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus using synthetic overlapping peptide libraryJ. Comb."/>
  <result pre="linear B-cell epitopes and entry-blocking peptide of severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus using synthetic overlapping peptide libraryJ. Comb. Chem.75200564865616153058"/>
  <result pre="and evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119230531947 106JonesJ.C.TurpinE.A.BultmannH.BrandtC.R.Schultz-CherryS.Inhibition of influenza" exact="virus infection" post="by a novel antiviral peptide that targets viral attachment"/>
  <result pre="evolution of pathogenic coronavirusesNat. Rev. Microbiol.17201918119230531947 106JonesJ.C.TurpinE.A.BultmannH.BrandtC.R.Schultz-CherryS.Inhibition of influenza virus" exact="infection" post="by a novel antiviral peptide that targets viral attachment"/>
  <result pre="influenza virus infection by a novel antiviral peptide that targets" exact="viral" post="attachment to cellsJ. Virol.80242006119601196717005658 107JoshiV.G.DigheV.D.ThakuriaD.MalikY.S.KumarS.Multiple antigenic peptide (MAP): a"/>
  <result pre="for diagnostic, antiviral and vaccine strategies for emerging and re-emerging" exact="viral" post="diseasesIndian J. Virol.243201331232024426293 108KadamR.U.JuraszekJ.BrandenburgB.BuyckC.SchepensW.B.G.KesteleynB.Potent peptidic fusion inhibitors of influenza"/>
  <result pre="Acad. Sci. U. S. A.106332009137971380119666568 114KshatriyaR.CachafeiroA.A.KerrR.J.NelsonJ.A.FiscusS.A.Comparison of two rapid human" exact="immunodeficiency" post="virus (HIV) assays, determine HIV-1/2 and OraQuick advance rapid"/>
  <result pre="regions of paramyxovirus fusion (F) proteins are potent inhibitors of" exact="viral" post="fusionProc. Natl. Acad. Sci. U. S. A.9351996218621918700906 117LeistnerC.M.Gruen-BernhardS.GlebeD.Role of"/>
  <result pre="Sci. U. S. A.9351996218621918700906 117LeistnerC.M.Gruen-BernhardS.GlebeD.Role of glycosaminoglycans for binding and" exact="infection" post="of hepatitis B virusCell. Microbiol.101200812213318086046 118LiJ.ChenY.YuanN.ZengM.ZhaoY.YuR.a novel natural influenza"/>
  <result pre="S. A.9351996218621918700906 117LeistnerC.M.Gruen-BernhardS.GlebeD.Role of glycosaminoglycans for binding and infection of" exact="hepatitis" post="B virusCell. Microbiol.101200812213318086046 118LiJ.ChenY.YuanN.ZengM.ZhaoY.YuR.a novel natural influenza a H1N1"/>
  <result pre="antiviral mechanismMar. Drugs16102018 119LiL.Epitope-based peptide vaccines predicted against novel coronavirus" exact="disease" post="caused by SARS-CoV-2bioRxiv2020 120LiX.WangB.LiuW.GuiM.PengZ.MengS.Blockage of conformational changes of heat"/>
  <result pre="by a alpha-helix peptide inhibits HER2 dimerization and signaling in" exact="breast" post="cancerPLoS One1042015e0124647 121LiawY.F.ChuC.M.Hepatitis B virus infectionLancet3739663200958259219217993 122LimE.K.GukK.KimH.ChungB.H.JungJ.Simple, rapid detection"/>
  <result pre="and immunogenicity from a phase I trial of inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccineAntivir. Ther.12720071107111318018769 124LinY.ShenX.YangR.F.LiY.X.JiY.Y.HeY.Y.Identification of an epitope"/>
  <result pre="immunogenicity from a phase I trial of inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccineAntivir. Ther.12720071107111318018769 124LinY.ShenX.YangR.F.LiY.X.JiY.Y.HeY.Y.Identification of an epitope of"/>
  <result pre="from a phase I trial of inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccineAntivir. Ther.12720071107111318018769 124LinY.ShenX.YangR.F.LiY.X.JiY.Y.HeY.Y.Identification of an epitope of SARS-coronavirus"/>
  <result pre="related human coronavirus diseasesACS Cent. Sci.63202031533132226821 127LiuQ.SomiyaM.KurodaS.Elucidation of the early" exact="infection" post="machinery of hepatitis B virus by using bio-nanocapsuleWorld J."/>
  <result pre="diseasesACS Cent. Sci.63202031533132226821 127LiuQ.SomiyaM.KurodaS.Elucidation of the early infection machinery of" exact="hepatitis" post="B virus by using bio-nanocapsuleWorld J. Gastroenterol.223820168489849627784961 128LiuZ.WangZ.LiuY.DongW.QiY.Analysis of"/>
  <result pre="GS-4774 as a therapeutic vaccine in virally suppressed patients with" exact="chronic hepatitis" post="BJ. Hepatol.653201650951627210427 130Lopez-MartinezR.Ramirez-SalinasG.L.Correa-BasurtoJ.BarronB.L.Inhibition of influenza a virus infection in"/>
  <result pre="as a therapeutic vaccine in virally suppressed patients with chronic" exact="hepatitis" post="BJ. Hepatol.653201650951627210427 130Lopez-MartinezR.Ramirez-SalinasG.L.Correa-BasurtoJ.BarronB.L.Inhibition of influenza a virus infection in"/>
  <result pre="patients with chronic hepatitis BJ. Hepatol.653201650951627210427 130Lopez-MartinezR.Ramirez-SalinasG.L.Correa-BasurtoJ.BarronB.L.Inhibition of influenza a" exact="virus infection" post="in vitro by peptides designed in silicoPLoS One8102013e76876 131LouZ.SunY.RaoZ.Current"/>
  <result pre="with chronic hepatitis BJ. Hepatol.653201650951627210427 130Lopez-MartinezR.Ramirez-SalinasG.L.Correa-BasurtoJ.BarronB.L.Inhibition of influenza a virus" exact="infection" post="in vitro by peptides designed in silicoPLoS One8102013e76876 131LouZ.SunY.RaoZ.Current"/>
  <result pre="and treatment-experienced HIV-infected patientsJ. Pharm. Sci.1031220144038404725291974 142MichelM.L.BourgineM.FontaineH.PolS.Therapeutic vaccines in treating" exact="chronic hepatitis" post="B: the end of the beginning or the beginning"/>
  <result pre="treatment-experienced HIV-infected patientsJ. Pharm. Sci.1031220144038404725291974 142MichelM.L.BourgineM.FontaineH.PolS.Therapeutic vaccines in treating chronic" exact="hepatitis" post="B: the end of the beginning or the beginning"/>
  <result pre="B virus peptide inhibitors: solution structures and interactions with the" exact="viral" post="capsidOrg. Biomol. Chem.132820157780778926100394 147NaitoT.IzumiK.KodamaE.SakagamiY.KajiwaraK.NishikawaH.SC29EK, a peptide fusion inhibitor with"/>
  <result pre="peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human" exact="immunodeficiency" post="virus type 1 mutants resistant to enfuvirtideAntimicrob. Agents Chemother.53320091013101819114674"/>
  <result pre="inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus" exact="type 1" post="mutants resistant to enfuvirtideAntimicrob. Agents Chemother.53320091013101819114674 148NiY.SonnabendJ.SeitzS.UrbanS.The pre-s2 domain"/>
  <result pre="resistant to enfuvirtideAntimicrob. Agents Chemother.53320091013101819114674 148NiY.SonnabendJ.SeitzS.UrbanS.The pre-s2 domain of the" exact="hepatitis" post="B virus is dispensable for infectivity but serves a"/>
  <result pre="Virol.93Pt 5201298098622258859 150Ning WangS.-Y.L.YangXing-LouHuangHui-MinZhangYu-JiGuoHuaLuoChu-MingMillerMaureenZhuGuangjianChmuraAleksei A.HaganEmilyZhouJi-HuaZhangYun-ZhiWangLin-FaDaszakPeterShiZheng-LiSerological evidence of Bat SARS-related coronavirus" exact="infection" post="in humans, ChinaVirol. Sin.3312018 151NyanguileO.Peptide antiviral strategies as an"/>
  <result pre="ChinaVirol. Sin.3312018 151NyanguileO.Peptide antiviral strategies as an alternative to treat" exact="lower" post="respiratory viral infectionsFront. Immunol.102019136631293570 152Oâ€™ConnellR.J.MerrittT.M.MaliaJ.A.VanCottT.C.DolanM.J.ZahwaH.Performance of the OraQuick rapid"/>
  <result pre="Sin.3312018 151NyanguileO.Peptide antiviral strategies as an alternative to treat lower" exact="respiratory" post="viral infectionsFront. Immunol.102019136631293570 152Oâ€™ConnellR.J.MerrittT.M.MaliaJ.A.VanCottT.C.DolanM.J.ZahwaH.Performance of the OraQuick rapid antibody"/>
  <result pre="151NyanguileO.Peptide antiviral strategies as an alternative to treat lower respiratory" exact="viral" post="infectionsFront. Immunol.102019136631293570 152Oâ€™ConnellR.J.MerrittT.M.MaliaJ.A.VanCottT.C.DolanM.J.ZahwaH.Performance of the OraQuick rapid antibody test"/>
  <result pre="of the OraQuick rapid antibody test for diagnosis of human" exact="immunodeficiency" post="virus type 1 infection in patients with various levels"/>
  <result pre="OraQuick rapid antibody test for diagnosis of human immunodeficiency virus" exact="type 1" post="infection in patients with various levels of exposure to"/>
  <result pre="antibody test for diagnosis of human immunodeficiency virus type 1" exact="infection" post="in patients with various levels of exposure to highly"/>
  <result pre="highly active antiretroviral therapyJ. Clin. Microbiol.41520032153215512734265 153OndiekiM.C.NyaribariM.C.EjekwumaduN.J.Nyakangâ€™oM.J.Design of a recombinant" exact="hepatitis" post="B vaccine based on stably binding HLA-I peptidesJ. Biomol."/>
  <result pre="cross-reactivity with SARS-CoVNat. Commun.1112020162032221306 156PassiouraT.WatashiK.FukanoK.ShimuraS.SasoW.MorishitaR.De Novo macrocyclic peptide inhibitors of" exact="hepatitis" post="B virus cellular entryCell Chem. Biol.2572018906-15 e5 157PeirisJ.S.LaiS.T.PoonL.L.GuanY.YamL.Y.LimW.Coronavirus as"/>
  <result pre="Chem. Biol.2572018906-15 e5 157PeirisJ.S.LaiS.T.PoonL.L.GuanY.YamL.Y.LimW.Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet361936620031319132512711465 158PenberthyW.T.ChariS.ColeA.L.ColeA.M.Retrocyclins and their activity against HIV-1Cell. Mol."/>
  <result pre="Biol.2572018906-15 e5 157PeirisJ.S.LaiS.T.PoonL.L.GuanY.YamL.Y.LimW.Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet361936620031319132512711465 158PenberthyW.T.ChariS.ColeA.L.ColeA.M.Retrocyclins and their activity against HIV-1Cell. Mol. Life"/>
  <result pre="their activity against HIV-1Cell. Mol. Life Sci.681320112231224221553001 159PetersenJ.DandriM.MierW.LutgehetmannM.VolzT.von WeizsackerF.Prevention of" exact="hepatitis" post="B virus infection in vivo by entry inhibitors derived"/>
  <result pre="against HIV-1Cell. Mol. Life Sci.681320112231224221553001 159PetersenJ.DandriM.MierW.LutgehetmannM.VolzT.von WeizsackerF.Prevention of hepatitis B" exact="virus infection" post="in vivo by entry inhibitors derived from the large"/>
  <result pre="HIV-1Cell. Mol. Life Sci.681320112231224221553001 159PetersenJ.DandriM.MierW.LutgehetmannM.VolzT.von WeizsackerF.Prevention of hepatitis B virus" exact="infection" post="in vivo by entry inhibitors derived from the large"/>
  <result pre="placebo-controlled phase I trialVaccine303120124655466022575166 165PoissonF.SeveracA.HouriouxC.GoudeauA.RoingeardP.Both pre-S1 and S domains of" exact="hepatitis" post="B virus envelope proteins interact with the core particleVirology228119971151209024817"/>
  <result pre="interact with the core particleVirology228119971151209024817 166PortalE.B.R.ProtParam Tool2020https://web.expasy.org/protparam/ 167PoutanenS.M.LowD.E.HenryB.FinkelsteinS.RoseD.GreenK.Identification of severe" exact="acute" post="respiratory syndrome in CanadaN. Engl. J. Med.3482020031995200512671061 168PredictorS.P.ANTIGENpro2020 169PuJ.WangQ.XuW.LuL.JiangS.Development"/>
  <result pre="with the core particleVirology228119971151209024817 166PortalE.B.R.ProtParam Tool2020https://web.expasy.org/protparam/ 167PoutanenS.M.LowD.E.HenryB.FinkelsteinS.RoseD.GreenK.Identification of severe acute" exact="respiratory" post="syndrome in CanadaN. Engl. J. Med.3482020031995200512671061 168PredictorS.P.ANTIGENpro2020 169PuJ.WangQ.XuW.LuL.JiangS.Development of"/>
  <result pre="the core particleVirology228119971151209024817 166PortalE.B.R.ProtParam Tool2020https://web.expasy.org/protparam/ 167PoutanenS.M.LowD.E.HenryB.FinkelsteinS.RoseD.GreenK.Identification of severe acute respiratory" exact="syndrome" post="in CanadaN. Engl. J. Med.3482020031995200512671061 168PredictorS.P.ANTIGENpro2020 169PuJ.WangQ.XuW.LuL.JiangS.Development of protein-"/>
  <result pre="HBV replication by upregulation of p53J. Gen. Virol.100820191241125231204972 171Qiushi LiuM.S.IijimaMasumiTatematsuaKenjiKurodaShunâ€™ichiA" exact="hepatitis" post="B virus-derived human hepatic cellspecific heparin-binding peptide: identification and"/>
  <result pre="deliveryMol. Pharm.15320181169117929436835 174Rerks-NgarmS.PitisuttithumP.NitayaphanS.KaewkungwalJ.ChiuJ.ParisR.Vaccination with ALVAC and AIDSVAX to prevent HIV-1" exact="infection" post="in ThailandN. Engl. J. Med.3612320092209222019843557 175ResourceI.A.MHC-II Binding Predictions2020 176RichardsonS.E.TellierR.MahonyJ.The"/>
  <result pre="J. Med.3612320092209222019843557 175ResourceI.A.MHC-II Binding Predictions2020 176RichardsonS.E.TellierR.MahonyJ.The laboratory diagnosis of severe" exact="acute" post="respiratory syndrome: emerging laboratory tests for an emerging pathogenClin."/>
  <result pre="Med.3612320092209222019843557 175ResourceI.A.MHC-II Binding Predictions2020 176RichardsonS.E.TellierR.MahonyJ.The laboratory diagnosis of severe acute" exact="respiratory" post="syndrome: emerging laboratory tests for an emerging pathogenClin. Biochem."/>
  <result pre="177RingelO.MullerK.KochJ.BrillB.WolfT.StephanC.Optimization of the EC26-2A4 epitope in the gp41 membrane proximal" exact="external" post="region targeted by neutralizing antibodies from an elite controllerAIDS"/>
  <result pre="with the peptide-based therapeutic HIV vaccine, vacc-4x, restores geometric mean" exact="viral" post="load set-point during treatment interruptionPLoS One1412019e0210965 179RutW.Substrate specificity profiling"/>
  <result pre="issue2006W202W20916844994 182SahaS.RaghavaG.P.Prediction of continuous B-cell epitopes in an antigen using" exact="recurrent" post="neural networkProteins6512006404816894596 183SapsfordK.E.Blanco-CanosaJ.B.DawsonP.E.MedintzI.L.Detection of HIV-1 specific monoclonal antibodies using"/>
  <result pre="in HIV reservoirsJ. Infect.756201755557128917661 192TassopoulosN.C.VolpesR.PastoreG.HeathcoteJ.ButiM.GoldinR.D.Efficacy of lamivudine in patients with" exact="hepatitis" post="B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic"/>
  <result pre="with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant)" exact="chronic hepatitis" post="B. lamivudine precore mutant study groupHepatology293199988989610051494 193TayM.Z.PohC.M.ReniaL.MacAryP.A.NgL.F.P.The trinity of"/>
  <result pre="hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic" exact="hepatitis" post="B. lamivudine precore mutant study groupHepatology293199988989610051494 193TayM.Z.PohC.M.ReniaL.MacAryP.A.NgL.F.P.The trinity of"/>
  <result pre="Rev. Immunol.2020 194TinocoA.D.SaghatelianA.Investigating endogenous peptides and peptidases using peptidomicsBiochemistry503520117447746121786763 195TiollaisP.PourcelC.DejeanA.The" exact="hepatitis" post="B virusNature317603719854894952995835 196ToxinPred. https://webs.iiitd.edu.in/raghava/toxinpred/index.html. 197TripathiS.WangG.WhiteM.QiL.TaubenbergerJ.HartshornK.L.Antiviral activity of the human"/>
  <result pre="a virusesPLoS One1042015e0124706 198TsengC.T.SbranaE.Iwata-YoshikawaN.NewmanP.C.GarronT.AtmarR.L.Immunization with SARS coronavirus vaccines leads to" exact="pulmonary" post="immunopathology on challenge with the SARS virusPLoS One742012e35421 199UhlP.HelmF.HofhausG.BringsS.KaufmanC.LeottaK.A"/>
  <result pre="199UhlP.HelmF.HofhausG.BringsS.KaufmanC.LeottaK.A liposomal formulation for the oral application of the investigational" exact="hepatitis" post="B drug myrcludex BEur. J. Pharm. Biopharm.103201615916627049970 200AIDS Data2020UNAIDS"/>
  <result pre="201v2.0 T. http://www.cbs.dtu.dk/services/TMHMM/. 202VemulaS.V.ZhaoJ.LiuJ.WangX.BiswasS.HewlettI.Current approaches for diagnosis of influenza virus" exact="infections" post="in humansViruses8420169627077877 203VolzT.AllweissL.BenM.M.WarlichM.LohseA.W.PollokJ.M.The entry inhibitor myrcludex-B efficiently blocks intrahepatic"/>
  <result pre="blocks intrahepatic virus spreading in humanized mice previously infected with" exact="hepatitis" post="B virusJ. Hepatol.585201386186723246506 204WalshC.T.Oâ€™BrienR.V.KhoslaC.Nonproteinogenic amino acid building blocks for"/>
  <result pre="Engl.522820137098712423729217 205WangG.Natural antimicrobial peptides as promising anti-HIV candidatesCurr. Top. Pept." exact="Protein" post="Res.1320129311026834391 206WatashiK.HBV slow maturation process leads to infectionTrends Microbiol.248201659759927345260"/>
  <result pre="leads to infectionTrends Microbiol.248201659759927345260 207WatashiK.SluderA.DaitoT.MatsunagaS.RyoA.NagamoriS.Cyclosporin a and its analogs inhibit" exact="hepatitis" post="B virus entry into cultured hepatocytes through targeting a"/>
  <result pre="transporter, sodium taurocholate cotransporting polypeptide (NTCP)Hepatology59520141726173724375637 208WHO. (https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b) 2015. 209WHO." exact="Hepatitis" post="B, https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b#:-:text=Hepatitis%20B%20is%20a%20potentially%20life-threatening%20liver%20infection,risk%20of%20death%20from%20cirrhosis%20and%20liver%20cancer; 2020. 210WiedersteinM.SipplM.J.ProSA-web: interactive web service for the"/>
  <result pre="Acids Res.35Web Server issue2007W407W401017517781 211WildC.OasT.McDanalC.BolognesiD.MatthewsT.A synthetic peptide inhibitor of human" exact="immunodeficiency" post="virus replication: correlation between solution structure and viral inhibitionProc."/>
  <result pre="of human immunodeficiency virus replication: correlation between solution structure and" exact="viral" post="inhibitionProc. Natl. Acad. Sci. U. S. A.8921199210537105411438243 212WinckelmannA.MorcillaV.ShaoW.SchleimannM.H.HojenJ.F.SchlubT.E.Genetic characterization"/>
  <result pre="enzymes of HIV-1Peptides32620111117112221539873 214World Health Organization Multicentre Collaborative Network for" exact="Severe" post="Acute Respiratory Syndrome DA multicentre collaboration to investigate the"/>
  <result pre="of HIV-1Peptides32620111117112221539873 214World Health Organization Multicentre Collaborative Network for Severe" exact="Acute" post="Respiratory Syndrome DA multicentre collaboration to investigate the cause"/>
  <result pre="HIV-1Peptides32620111117112221539873 214World Health Organization Multicentre Collaborative Network for Severe Acute" exact="Respiratory" post="Syndrome DA multicentre collaboration to investigate the cause of"/>
  <result pre="214World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory" exact="Syndrome" post="DA multicentre collaboration to investigate the cause of severe"/>
  <result pre="Syndrome DA multicentre collaboration to investigate the cause of severe" exact="acute" post="respiratory syndromeLancet361937020031730173312767752 215WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.L.AbionaO.Cryo-EM structure of the 2019-nCoV spike in"/>
  <result pre="DA multicentre collaboration to investigate the cause of severe acute" exact="respiratory" post="syndromeLancet361937020031730173312767752 215WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.L.AbionaO.Cryo-EM structure of the 2019-nCoV spike in the"/>
  <result pre="biomedical scienceJ. Biomed. Sci.232016826786672 219WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature5797798202026526932015508 220WyattR.SodroskiJ.The HIV-1 envelope glycoproteins: fusogens, antigens,"/>
  <result pre="scienceJ. Biomed. Sci.232016826786672 219WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature5797798202026526932015508 220WyattR.SodroskiJ.The HIV-1 envelope glycoproteins: fusogens, antigens, and"/>
  <result pre="glycoproteins: fusogens, antigens, and immunogensScience28053711998188418889632381 221XiaS.LiuM.WangC.XuW.LanQ.FengS.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="helical short-peptide fusion inhibitor with highly potent activity against human" exact="immunodeficiency" post="virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virusJ."/>
  <result pre="fusion inhibitor with highly potent activity against human immunodeficiency virus" exact="type 1" post="(HIV-1), HIV-2, and simian immunodeficiency virusJ. Virol.9112017 224XuD.Z.WangX.Y.ShenX.L.GongG.Z.RenH.GuoL.M.Results of"/>
  <result pre="against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian" exact="immunodeficiency" post="virusJ. Virol.9112017 224XuD.Z.WangX.Y.ShenX.L.GongG.Z.RenH.GuoL.M.Results of a phase III clinical trial"/>
  <result pre="clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for" exact="chronic hepatitis" post="B patients: experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of"/>
  <result pre="trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic" exact="hepatitis" post="B patients: experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of"/>
  <result pre="hepatitis B patients: experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of" exact="hepatitis" post="B virus infection by a preS1-binding peptideSci. Rep.620162939127384014 226YoshikawaM.Bioactive"/>
  <result pre="patients: experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of hepatitis B" exact="virus infection" post="by a preS1-binding peptideSci. Rep.620162939127384014 226YoshikawaM.Bioactive peptides derived from"/>
  <result pre="experiences and findingsJ. Hepatol.593201345045623669281 225YeX.ZhouM.HeY.WanY.BaiW.TaoS.Efficient inhibition of hepatitis B virus" exact="infection" post="by a preS1-binding peptideSci. Rep.620162939127384014 226YoshikawaM.Bioactive peptides derived from"/>
  <result pre="unique B cell epitope-based particulate vaccine shows effective suppression of" exact="hepatitis" post="B surface antigen in miceGut692202034335430926653 230ZhaoH.A broad-spectrum virus- and"/>
  <result pre="broad-spectrum virus- and host-targeting antiviral peptide against SARS-CoV-2 and other" exact="respiratory" post="virusesNat. Res.2020 231ZhaoH.ZhouJ.ZhangK.ChuH.LiuD.PoonV.K.A novel peptide with potent and broad-spectrum"/>
  <result pre="novel peptide with potent and broad-spectrum antiviral activities against multiple" exact="respiratory" post="virusesSci. Rep.620162200826911565 232ZhengB.J.GuanY.HezM.L.SunH.DuL.ZhengY.Synthetic peptides outside the spike protein heptad"/>
  <result pre="coronavirusAntivir. Ther.103200539340315918330 233ZhouS.LiuR.BaroudyB.M.MalcolmB.A.ReyesG.R.The effect of ribavirin and IMPDH inhibitors on" exact="hepatitis C" post="virus subgenomic replicon RNAVirology3102200333334212781720 234ZhuX.ZhuY.YeS.WangQ.XuW.SuS.Improved pharmacological and structural properties"/>
 </snippets>
</snippetsTree>
